TheraRadar
Clinical-Stage Companies / Suzhou Suncadia Biopharmaceuticals

Suzhou Suncadia Biopharmaceuticals

Pre-Approval PRO BETA
78
Total Trials
25
Phase 3
39
Phase 2
55
Recruiting
928
Score

Pipeline by Phase

Phase 3
25
Phase 2
39
Phase 1
37

Therapeutic Focus

Advanced Solid Tumors Advanced Solid Tumor Malignant Solid Tumors Ovarian Cancer Advanced Hepatocellular Carcinoma

Clinical Trials (78)

NCT06618664 Phase 3 RECRUITING

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Started: 10/28/2024

NCT07183189 Phase 3 RECRUITING

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Started: 10/30/2025

NCT07418749 Phase 3 RECRUITING

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Started: 3/30/2026

NCT07393542 Phase 3 RECRUITING

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Started: 2/12/2026

NCT07118527 Phase 3 RECRUITING

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Started: 8/18/2025

NCT07229625 Phase 3 RECRUITING

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Started: 1/21/2026

NCT07111832 Phase 3 RECRUITING

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Started: 8/20/2025

NCT07170995 Phase 3 RECRUITING

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Started: 10/22/2025

NCT06929624 Phase 3 RECRUITING

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Started: 4/24/2025

NCT06860750 Phase 3 RECRUITING

A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis

Started: 4/29/2025

NCT06640257 Phase 3 RECRUITING

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Started: 11/4/2024

NCT06394492 Phase 3 RECRUITING

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Started: 5/10/2024

NCT06671379 Phase 3 ACTIVE NOT RECRUITING

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Started: 11/29/2024

NCT07424287 Phase 3 NOT YET RECRUITING

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Started: 6/1/2026

NCT06199973 Phase 3 ACTIVE NOT RECRUITING

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Started: 3/1/2024

NCT05179239 Phase 3 TERMINATED

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Started: 2/26/2022

NCT04950322 Phase 3 ACTIVE NOT RECRUITING

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Started: 12/6/2021

NCT06833307 Phase 3 NOT YET RECRUITING

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Started: 2/1/2025

NCT05134194 Phase 3 TERMINATED

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Started: 1/17/2022

NCT07489716 Phase 2 RECRUITING

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Started: 4/29/2026

NCT07454720 Phase 2 RECRUITING

A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer

Started: 3/23/2026

NCT07450976 Phase 2 RECRUITING

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Started: 3/25/2026

NCT07071714 Phase 2 RECRUITING

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Started: 7/22/2025

NCT07028281 Phase 2 RECRUITING

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Started: 7/8/2025

NCT05671822 Phase 2 RECRUITING

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Started: 3/14/2023

NCT07110571 Phase 2 RECRUITING

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Started: 8/28/2025

NCT07028268 Phase 2 RECRUITING

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Started: 6/24/2025

NCT06879145 Phase 2 RECRUITING

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Started: 4/25/2025

NCT06844474 Phase 2 RECRUITING

A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

Started: 3/7/2025

NCT06778031 Phase 2 RECRUITING

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Started: 2/26/2025

NCT05300269 Phase 2 RECRUITING

SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Started: 7/5/2022

NCT06247956 Phase 2 ACTIVE NOT RECRUITING

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Started: 3/11/2024

NCT05149807 Phase 2 TERMINATED

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Started: 1/26/2022

NCT04856787 Phase 2 TERMINATED

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Started: 6/22/2021

NCT06465563 Phase 2 ACTIVE NOT RECRUITING

SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Started: 7/1/2024

NCT05394857 Phase 2 TERMINATED

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Started: 9/13/2022

NCT05055934 Phase 2 COMPLETED

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Started: 10/22/2021

NCT06592625 Phase 2 NOT YET RECRUITING

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Started: 9/20/2024

NCT04840485 Phase 2 COMPLETED

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Started: 6/9/2021

NCT06211023 Phase 2 NOT YET RECRUITING

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Started: 2/15/2024

NCT07298772 Phase 1 RECRUITING

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Started: 1/7/2026

NCT07478302 Phase 1 RECRUITING

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Started: 4/14/2026

NCT06484777 Phase 1 RECRUITING

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Started: 8/7/2024

NCT07229638 Phase 1 RECRUITING

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Started: 2/27/2026

NCT07414602 Phase 1 RECRUITING

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

Started: 3/16/2026

NCT07239596 Phase 1 RECRUITING

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Started: 1/6/2026

NCT07123129 Phase 1 RECRUITING

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

Started: 8/28/2025

NCT07275242 Phase 1 RECRUITING

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

Started: 12/23/2025

NCT06737731 Phase 1 RECRUITING

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

Started: 1/21/2025

NCT06703177 Phase 1 RECRUITING

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Started: 2/18/2025

NCT06618651 Phase 1 RECRUITING

A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors

Started: 11/13/2024

NCT06840002 Phase 1 RECRUITING

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Started: 3/18/2025

NCT07068932 Phase 1 RECRUITING

A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors

Started: 7/22/2025

NCT07059221 Phase 1 RECRUITING

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Started: 7/11/2025

NCT07009457 Phase 1 RECRUITING

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

Started: 6/16/2025

NCT06859775 Phase 1 RECRUITING

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Started: 4/25/2025

NCT06907628 Phase 1 RECRUITING

A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors

Started: 4/2/2025

NCT06754930 Phase 1 RECRUITING

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Started: 2/18/2025

NCT06094556 Phase 1 RECRUITING

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Started: 12/25/2023

NCT06443489 Phase 1 RECRUITING

A Trial of SHR-4849 in Advanced Solid Tumors

Started: 6/26/2024

NCT06764628 Phase 1 RECRUITING

A Study of SHR-4375 in Subjects With Solid Tumors

Started: 1/9/2025

NCT06643754 Phase 1 RECRUITING

A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors

Started: 12/10/2024

NCT05819684 Phase 1 RECRUITING

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Started: 4/18/2023

NCT05444088 Phase 1 RECRUITING

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Started: 8/2/2022

NCT05416775 Phase 1 RECRUITING

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Started: 8/15/2022

NCT06434103 Phase 1 WITHDRAWN

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Started: 10/10/2024

NCT06380881 Phase 1 COMPLETED

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

Started: 5/20/2024

NCT07229612 Phase 1 NOT YET RECRUITING

A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors

Started: 11/1/2025

NCT06381050 Phase 1 COMPLETED

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Started: 5/24/2024

NCT05394818 Phase 1 COMPLETED

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Started: 7/21/2022

NCT05765032 Phase 1 ACTIVE NOT RECRUITING

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Started: 12/30/2022

NCT04856774 Phase 1 COMPLETED

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Started: 6/1/2021

NCT06182384 Phase 1 COMPLETED

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Started: 12/24/2023

NCT06131216 Phase 1 NOT YET RECRUITING

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Started: 12/1/2023

NCT05503888 Phase 1 NOT YET RECRUITING

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Started: 10/1/2022

NCT07661537 Phase 1 NOT YET RECRUITING

A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

Started: 6/1/2026

NCT07652281 Phase 1 NOT YET RECRUITING

A Clinical Study of SHR-5421 in Patients With Multiple Myeloma

Started: 6/1/2026

NCT06779097 Phase 4 NOT YET RECRUITING

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Started: 2/1/2025

Drug Candidates

SHR-1826 Adebrelimab in combination with SHR-8068 and chemotherapy Adebrelimab combined with chemotherapy SHR-8068 SHR-4375 Injection SHR-2524 Injection SHR-9539 for injection SHR-A2009 ; Aumolertinib SHR-A1921;Adebrelimab;SHR-8068;carboplatin SHR-A2102 for Injection
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 8/6/2025
Trials (12 months): 26
Completed Trials: 7
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.